

PERSONAL INFORMATION **Prof. Fausto Baldanti**



**📍 Affiliations**  
 University of Pavia, Dpt. Clinical, Surgical, Diagnostic and Pediatric Sciences, 27100 Pavia, Italy  
 Fondazione IRCCS Policlinico San Matteo, Microbiology and Virology Dpt, 27100 Pavia, Italy

**☎ +39 0382502283 (+39 0382502420 Secretariat)**

**✉ [fausto.baldanti@unipv.it](mailto:fausto.baldanti@unipv.it)**

Enterprise	University	EPR
<input type="checkbox"/> Management Level	<input checked="" type="checkbox"/> Full professor	<input checked="" type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist / Principal Investigator
<input checked="" type="checkbox"/> Mid-Management Level	<input type="checkbox"/> Associate Professor	<input type="checkbox"/> Level III Researcher and Technologist
<input type="checkbox"/> Employee / worker level	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

**WORK EXPERIENCE**

Replace with dates (from - to) **2020-today: Full Professor**, University of Pavia, Pavia (Italy): Virology and Clinical Virology, School of Medicine (Golgi Course in Italian); Virology and Clinical Virology, School of Medicine (Harvey Course in English); Diagnostic Virology, School of Biotechnology; Clinical Microbiology, Nursing School.

**2014-2020 Associated Professor**, University of Pavia, Pavia (Italy): Virology and Clinical Virology, School of Medicine (Golgi Course in Italian); Virology and Clinical Virology, School of Medicine (Harvey Course in English); Diagnostic Virology, School of Biotechnology; Clinical Microbiology, Nursing School.

**2017-today: Director**, Specialization School in Microbiology and Virology, University of Pavia

**2018-today: Professor**, Clinical Virology, Gastroenterology Specialization School, University of Pavia  
**2018-today: Professor**, Clinical Virology, Pathology Specialization School, University of Pavia  
**2014-today: Professor**, Clinical Virology, Infectious Diseases Specialization School, University of Pavia

**2021-today: Director**, Microbiology and Virology Dpt, Fondazione IRCCS Policlinico San Matteo, Pavia  
**2010-2020: Director**, Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia

**2013-2014: Contract Professor**, Virology, School of Biotechnology, University of Pavia,  
**2012- 2014: Contract Professor**, Virology, School of Medicine (Harvey Course in English) University Pavia,  
**2011-2012: Contract Professor**, School for Laboratory Technicians, University of Pavia,  
**2010-2011: Contract Professor**, Microbiology and Virology Specialization School, University of Pavia,  
**2009-2011: Contract Professor**, Virology, School of Biotechnology, University of Pavia,  
**2004-2005: Contract Professor**, Virology, School of Biotechnology, Vita-Salute San Raffaele University, Milano (Italy)  
**1998-2014: Contract Professor**, Infectious Diseases Specialization School, University of Pavia

**1994-2010: Resident-MD**, Fondazione IRCCS Policlinico San Matteo, Pavia, with functions of Supervisor of Molecular Virology Lab and Research and Development Lab (MOGM II plant) at the “Servizio di Virologia” Unit.

**EDUCATION AND TRAINING**

Replace with dates (from - to)

**2022-2023** Coordinator I-level Master “Molecular Diagnostics”, University of Pavia  
**2022-2023** Coordinator I-Level Master “Management in Nursing”, University of Pavia  
**2021-2022** Co-coordinator II -level Master “Advanced Diagnostics in Microbiology”, University of Pavia (6<sup>th</sup> Edition)  
**2021 Co-Coordinator** Pavia Intensive School for Advanced Graduate Studies “Emerging viral threats in a globalized society: molecular, epidemiological, and social aspects of emerging viral diseases”  
**2004:** Specialization in Microbiology and Virology, University of Padua, Italy (70/70 cum Laude)  
**1995:** Specialization in Infectious Diseases, University of Pavia, (50/50 cum Laude).  
**1990:** Degree in Medicine, University of Pavia (110/110 cum Laude).

## WORK ACTIVITIES

**Awards** **2017:** ESCMID Fellow, from the European Society for Clinical Microbiology and Infectious Diseases  
**1997:** “Heine-Medin Medal” from the European Society for Clinical Virology

**2018-today** European Society for Clinical Virology, ESCV (Communication Officer 2018-2020)  
**2013-2019** European Society for Clinical Virology, ESCV (2<sup>nd</sup> Vice President 2013-2019)  
**2018-today** Board member, Associazione Microbiologi Clinici Italiani  
**2019-today** Member of the Working Group on CMV infections of the European Society for Organ Transplantation (ESOT)  
**2020-2022** Regional Delegate of the Società Italiana di Microbiologia (SIM)

Member, European Society for Clinical Virology and Infectious Diseases, ESCMID  
 Member, Società Italiana di Virologia Medica, SIVM  
 Member, Società Italiana di Microbiologia, SIM

**1994-2005** Member of International Society for Antiviral Research, ISAR (1994-2005)  
**1994-2010** Member of American Society for Microbiology, ASM (1994-2010)

Member of **Comitato Scientifico della Fondazione Regionale per la Ricerca Biomedica (FRRB)**;  
 Membro of **Comitato Tecnico Scientifico dell’Istituto Nazionale per le Malattie Infettive “Lazzaro Spallanzani”**, Roma, dal 18 febbraio 2019

**Editorial activity** **2021-today** Associate Editor, Frontiers in Microbiology  
**2012-2020** Associated Editor, Journal of Clinical Virology  
**2013-2016** Associated Editor PLoS ONE  
**2013-today** Associated Editor New Microbiologica  
**2013-today** Member Editorial Board, New Microbiologica  
**2011-2012** Member Editorial Board, Antiviral Research  
**2010-2012** Committee for Internal Audit, Journal of Clinical Virology  
**2009-2012** Member Editorial Board, Journal of Clinical Virology

**Referee (among others) for:** Haematologica; Antiviral Research; Journal of Antimicrobial Chemotherapy; Journal of Clinical Virology; Clinical Microbiology and Infection; BioMed Central Infectious Diseases; Journal of Infectious Diseases; Antimicrobial Agents and Chemotherapy; Journal of General Virology; European Journal of Infectious Diseases and Clinical Microbiology; Clinical Infectious Diseases; Journal of Medical Virology; BioMed Central Critical Care; Liver Transplantation; Transplant Infectious Diseases; Diagnostic Microbiology and Infectious Diseases; Archives of Virology; HIV Therapy; Current HIV Research; PLoS One; Antiviral Chemistry & Chemotherapy; Emerging Infectious Diseases; Eurosurveillance; Future Virology, Frontiers in Microbiology.

**Invited presentations** As of today, more than 200 invited speeches were delivered at National and International Conferences  
 Here follows the list of invited presentations of the last 3 months (January 01, 2022-March 30, 2022)  
 Lecture “Diagnostic developments and innovation”, EXPO DUBAI Conference, Dubai, Jan 31, 2022  
 Lecture “COVID-19: perché vaccinare i bambini? Webinar “Frontiere in Medicina dell’età evolutiva: un’ora di riflessioni”, March 29, 2022  
 Lecture “20.02.2020 h 20.00”, Workshop “Fighting COVID-19: Basic and translational research”, Faculty of Medicine, Rijeka, Croatia, March 22, 2022  
 Lecture “HPV e tumore della cervice uterine”, 9° Convegno Oncologico I tumori femminili: prevenzione, cura e ricerca, University of Pavia, Pavia, March 25, 2022  
 Lecture “Old and new treatment options”, Virtual 8th International Congenital CMV Conference and 18th International CMV Workshop, March 28 - April 1, 2022

- Grants** Since 1994 grants for more than 50 research projects (either monocentric or multicentric) were obtained from: i) Italian Ministry of Health; ii) Italian Ministry of Research ; iii) Italian National Institute of Health; iv) CNR (National Research Council), as well as other public Entities v) Corporate Entities, vi) International Institutions. Here follows a list of the grants obtained in the last 10 years:  
Principal Investigator PNRR Extended Partnership project PE.13 title: ONE HEALTH BASIC AND TRANSLATIONAL RESEARCH ACTIONS (INF-ACT), funded by the European Union - NextGenerationEU, 01-11-2022 to date  
Horizon 2020 - "Antibody therapy against coronavirus (COVID-2019)", project acronym ATAC (coordinator Fondazione IRCCS Policlinico San Matteo), 01/04/2020-01/04/2022;  
Call Ricerca Finalizzata Italian Ministry of Health PE-2016-02362470, title "Signature of immune protection from human cytomegalovirus infection and their application to a vaccine design", (coordinator Fondazione IRCCS Policlinico San Matteo) 01/12/2018-30/11/2022;  
Call Ricerca Finalizzata COVID19, 2020-12371760 Italian Ministry of Health, title "Baseline immunity status effect on SARs-Cov-2 presentation and evolution: comparison between immunocompetent and immunocompromised patients (BIAS)", (coordinator Fondazione IRCCS Policlinico San Matteo), 08/11/2020-07/02/2022;  
Call COVID Italian Ministry of Health "Exploiting immunopathogenic mechanisms for establishing predictive markers, diagnostic tools and medical countermeasures in COVID-19" (Coordinator INMI-National Institute for Infectious Disease "Lazzaro Spallanzani" IRCCS), 01/11/2020-31/10/2021;  
Call Ricerca Finalizzata Italian Ministry of Health 2019-12370797, title "Novel prediction markers for preventing Human Cytomegalovirus (HCMV) reactivation in the era of game changer inhibitors of viral packaging and egress" (coordinator Fondazione IRCCS Policlinico San Matteo), 15/06/2021-14/06/2024;  
Call Ricerca Finalizzata 2014 Italian Ministry of Health "Development and validation of new assays for diagnosis and monitoring of infectious diseases using the DiaSorin Q-LAMP Technology", (coordinator Fondazione IRCCS Policlinico San Matteo) 01/09/2016-31/08/2020;  
Call Ricerca Finalizzata 2014 Italian Ministry of Health "Identification and characterization of human broadly neutralizing antibodies against human coronaviruses and human parainfluenza viruses" (coordinator Fondazione IRCCS Policlinico San Matteo) 01/09/2016-31/08/2020;  
Ricerca Corrente 2021 Fondazione IRCCS Policlinico San Matteo, title "In vitro model for the study of SARS-CoV-2 infection of lung" acronym VISION, 01/07/2021-01/07/2024;  
Ricerca Corrente 2017 "Isolamento di phlebovirus da flebotomi e valutazione sierologica della loro diffusione nell'uomo e negli animali domestici" (coordinator Istituto Zooprofilattico Sperimentale della Lombardia ed Emilia Romagna), 15/05/2017-14/05/2021;  
Serum Genetic Covid-19 project (acronym SerGenCOVID-19): Indagine sierologica e genetica sull'immunità e la suscettibilità all'infezione da SARS-CoV-2 e creazione di una biobanca (coordinator Institute of Molecular Genetics IGM-CNR, Roma), 01/01/2021-31/12/2023;  
Centro Nazionale per la Prevenzione ed il Controllo delle Malattie - PROGRAMMA CCM 2021, project title "Studio pilota per la sorveglianza epidemiologica e virologica del Virus Respiratorio Sinciziale in Italia" (coordinator Italian National Institute of Health);  
Ricerca Corrente Fondazione IRCCS Policlinico San Matteo "Valutazione della risposta T-cellulare nel controllo delle infezioni virali nel paziente immunocompromesso", PI Prof. F. Baldanti, 01/07/2014-01/07/2020;  
Ricerca Corrente Fondazione IRCCS Policlinico San Matteo "Evaluation of depth and breath of immune impairment in solid organ (SOT) and hematopoietic stem cell transplant (HSCT) recipients as predictors of the risk for infectious complications" PI Prof. F. Baldanti, 01/04/2017-01/04-2022.
- Patents** Co-inventor of patent "Compound with DDX3 inhibitory activity and their use as anti-HIV, anti-cancer therapeutic", pubblicato il 2011/4/7 (n. WO/2011/039735).

## PERSONAL SKILLS

Mother tongue(s)	Italian
Other language(s)	English, fluent
Job-related skills	Leadership, mediation, public speech, job organization, analytical as well as synthetic thinking, prospective thinking, out-of-the-box solutions attitude
Digital skills	Word, ppt, excel, Zoom and other communication platforms
Other skills	Fly fishing, fly tying, drawing, sculpture, avid reader

## ADDITIONAL INFORMATION

**Statement of Research Interests**

i) development and clinical validation of novel molecular, serological and immunological assays for diagnosis of viral diseases; ii) study of pathogenetic aspects of viral infections during pregnancy and identification of prognostic parameters; iii) study of pathogenesis of viral infectious opportunistic infections in immunocompromised individuals and identification of molecular and immunologic markers of disease risk and disease progression; iv) molecular epidemiology of emerging (Arboviruses, Picornaviruses, HEV etc.) and re-emerging (rubella, measles etc.) viral infections and development of novel diagnostic assays for virulence factors detection; v) molecular epidemiology of emerging and re-emerging respiratory viral infections (Influenzaviruses, Coronaviruses, Picornaviruses, Paramixoviruses etc.) and development of novel diagnostic assays for virulence factors detection at the interface human-animal hosts; vi) development of human monoclonal antibodies for the treatment of emerging viral threats; vii) pathogenesis of virus-related tumors; viii) molecular mechanisms of viral drug-resistance

**Publications**

Total number of publications in peer-review journals: 539 (Scopus, at 4/06/2024)  
 total number of citations: (19963, Scopus, at 4/06/2024)  
 H index (Scopus): 67 (Scopus, at 4/06/2024)

**Here follows a selection of 10 papers in the last 10yrs relevant to the different topics of the project, with a specific focus on emerging respiratory and vector-borne viral threats.**

**The following papers describe the experience of Baldanti in coordinating studies aimed at discover new respiratory virus threats.**

Rovida F, Piralla A, Marzani FC, Moreno A, Campanini G, Mojoli F, Pozzi M, Girello A, Chiapponi C, Vezzoli F, Prati P, Percivalle E, Pavan A, Gramegna M, Iotti GA, **Baldanti F**. Swine influenza A (H1N1) virus (SIV) infection requiring extracorporeal life support in an immunocompetent adult patient with indirect exposure to pigs, Italy, October 2016. *Euro Surveill.* 2017 Feb;22(5):30456. doi: 10.2807/1560-7917.ES.2017.22.5.30456.

Piralla A, Moreno A, Orlandi ME, Percivalle E, Chiapponi C, Vezzoli F, **Baldanti F**; Influenza Surveillance Study Group. Swine Influenza A(H3N2) Virus Infection in Immunocompromised Man, Italy, 2014. *Emerg Infect Dis.* 2015 Jul;21(7):1189-91. doi: 10.3201/eid2107.140981.

**The following papers show the experience of Baldanti's research group in coordinating studies aimed at monitoring emerging viral threats as well as in serological and molecular epidemiology of respiratory and vector borne viruses.**

Percivalle E, Cambiè G, Cassaniti I, Nepita EV, Maserati R, Ferrari A, Di Martino R, Isemia P, Mojoli F, Bruno R, Tirani M, Cereda D, Nicora C, Lombardo M, **Baldanti F**. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. *Euro Surveill.* 2020 Jun;25(24):2001031. doi: 10.2807/1560-7917.ES.2020.25.24.2001031. Erratum in: *Euro Surveill.* 2022 Jan;27(3)

Alteri C, Cento V, Piralla A, Costabile V, Tallarita M, Colagrossi L, Renica S, Giardina F, Novazzi F, Gaiarsa S, Matarazzo E, Antonello M, Vismara C, Fumagalli R, Epis OM, Puoti M, Pemo CF, Baldanti F. Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy. *Nat Commun.* 2021 Jan 19;12(1):434. doi: 10.1038/s41467-020-20688-x.

Percivalle E, Cassaniti I, Calzolari M, Lelli D, **Baldanti F**. Thirteen Years of Phleboviruses Circulation in Lombardy, a Northern Italy Region. *Viruses.* 2021 Jan 29;13(2):209. doi: 10.3390/v13020209.

Pellegrinelli L, Giardina F, Lunghi G, Uceda Renteria SC, Greco L, Fratini A, Galli C, Piralla A, Binda S, Pariani E, **Baldanti F**. Emergence of divergent enterovirus (EV) D68 sub-clade D1 strains, northern Italy, September to October 2018. *Euro Surveill.* 2019 Feb;24(7):1900090. doi: 10.2807/1560-7917.ES.2018.24.7.1900090.

Piralla A, Mariani B, Rovida F, **Baldanti F**. Frequency of respiratory viruses among patients admitted to 26 Intensive Care Units in seven consecutive winter-spring seasons (2009-2016) in Northern Italy. *J Clin Virol.* 2017 Jul;92:48-51. doi: 10.1016/j.jcv.2017.05.004.

Rovida F, Brianese N, Piralla A, Sarasini A, Girello A, Giardina F, Cassaniti I, Fornabaio C, Seminari E, Monteverdi A, Piro A, Baggieri M, Cereda D, Pan A, Magurano F, **Baldanti F**. Outbreak of measles genotype H1 in Northern Italy originated from a case imported from Southeast Asia, 2017. *Clin Microbiol Infect.* 2019 Apr;25(4):526-528. doi: 10.1016/j.cmi.2018.09.027.

**The following papers show the experience of Baldanti in coordinating studies on the pathogenesis of respiratory and vector-borne viral diseases**

Cassaniti I, Bergami F, Percivalle E, Gabanti E, Sammartino JC, Ferrari A, Adzasehoun KMG, Zavaglio F, Zelini P, Comolli G, Sarasini A, Piralla A, Ricciardi A, Zuccaro V, Maggi F, Novazzi F, Simonelli L, Varani L, Lilleri D, **Baldanti F**. Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. *Clin Microbiol Infect*. 2022 Feb;28(2):301.e1-301.e8. doi: 10.1016/j.cmi.2021.09.016.

Rovida F, Cassaniti I, Paolucci S, Percivalle E, Sarasini A, Piralla A, Giardina F, Sammartino JC, Ferrari A, Bergami F, Muzzi A, Novelli V, Meloni A, Cutti S, Grugnetti AM, Grugnetti G, Rona C, Daglio M, Marena C, Triarico A, Lilleri D, **Baldanti F**. SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. *Nat Commun*. 2021 Oct 15;12(1):6032. doi: 10.1038/s41467-021-26154-6.

Cassaniti I, Bergami F, Arena F, Sammartino JC, Ferrari A, Zavaglio F, Curti I, Percivalle E, Meloni F, Pandolfi L, Pellegrini C, Turco A, Seminari E, Pattonieri EF, Gregorini M, Rampino T, Sarasini A, Lilleri D, **Baldanti F**. Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant. *Microorganisms*. 2021 Dec 18;9(12):2622. doi: 10.3390/microorganisms9122622.

**The following papers show the experience of Baldanti in participating in large collaborative studies aimed at finding novel preventive and therapeutic solutions for respiratory and vector-borne viral threats**

De Gasparo R, Pedotti M, Simonelli L, Nickl P, Muecksch F, Cassaniti I, Percivalle E, Lorenzi JCC, Mazzola F, Magri D, Michalcikova T, Haviernik J, Honig V, Mrzkova B, Polakova N, Fortova A, Tureckova J, Iatsiuk V, Di Girolamo S, Palus M, Zudova D, Bednar P, Bukova I, Bianchini F, Mehn D, Nencka R, Strakova P, Pavlis O, Rozman J, Gioria S, Sammartino JC, Giardina F, Gaiarsa S, Pan-Hammarström Q, Barnes CO, Bjorkman PJ, Calzolari L, Piralla A, **Baldanti F**, Nussenzweig MC, Bieniasz PD, Hatzioannou T, Prochazka J, Sedlacek R, Robbiani DF, Ruzek D, Varani L. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. *Nature*. 2021 May;593(7859):424-428. doi: 10.1038/s41586-021-03461-y. Epub 2021 Mar 25. Erratum in: *Nature*. 2021 Sep;597(7874):E2. PMID: 33767445.

Ronchi A, Pietrasanta C, Zavattoni M, Saruggia M, Schena F, Sinelli MT, Agosti M, Tzialla C, Varsalone FF, Testa L, Ballerini C, Ferrari S, Mangili G, Ventura ML, Perniciaro S, Spada E, Lunghi G, Piralla A, **Baldanti F**, Mosca F, Pugni L. Evaluation of Rooming-in Practice for Neonates Born to Mothers With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Italy. *JAMA Pediatr*. 2021 Mar 1;175(3):260-266. doi: 10.1001/jamapediatrics.2020.5086. PMID: 33284345; PMCID: PMC7921895.

Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, Guarino B, Silacci C, Marcandalli J, Marsland BJ, Piralla A, Percivalle E, Sallusto F, **Baldanti F**, Lanzavecchia A. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. *Nature*. 2013 Sep 19;501(7467):439-43. doi: 10.1038/nature12442. Epub 2013 Aug 18. PMID: 23955151.